MCID: LRG017
MIFTS: 59

Large Intestine Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Large Intestine Cancer

MalaCards integrated aliases for Large Intestine Cancer:

Name: Large Intestine Cancer 12 15
Neoplasm of the Large Intestine 6
Colorectal Neoplasms 44

Classifications:



External Ids:

Disease Ontology 12 DOID:5672
ICD10 33 C18.9
MeSH 44 D015179
SNOMED-CT 68 93854002

Summaries for Large Intestine Cancer

Disease Ontology : 12 An intestinal cancer that effects the long, tube-like organ that is connected to the small intestine at one end and the anus at the other.

MalaCards based summary : Large Intestine Cancer, also known as neoplasm of the large intestine, is related to lynch syndrome and colorectal cancer. An important gene associated with Large Intestine Cancer is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Tegafur and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and testes, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Large Intestine Cancer

Diseases in the Small Intestine Cancer family:

Large Intestine Cancer Intestine Carcinoma in Situ

Diseases related to Large Intestine Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 33.5 APC BRAF CTNNB1 EGFR KRAS TP53
2 colorectal cancer 32.9 AKT1 APC BRAF CTNNB1 EGFR ERBB2
3 gastric cancer 31.0 AKT1 APC CTNNB1 EGFR ERBB2 KRAS
4 familial adenomatous polyposis 30.8 APC CTNNB1 KRAS SMAD4 TP53
5 intestinal disease 30.7 AKT1 CTNNB1 EGFR HRAS KRAS PIK3CA
6 large intestine adenocarcinoma 11.0
7 anus cancer 11.0
8 hepatocellular carcinoma 10.9 AKT1 APC CTNNB1 EGFR GNAS HRAS
9 lung cancer susceptibility 3 10.9 AKT1 APC BRAF CTNNB1 EGFR ERBB2
10 adenocarcinoma 10.9 AKT1 APC BRAF CTNNB1 EGFR ERBB2
11 gastric adenocarcinoma 10.9 AKT1 APC BRAF CTNNB1 EGFR ERBB2
12 cholangiocarcinoma 10.9 AKT1 APC BRAF CTNNB1 EGFR ERBB2
13 breast cancer 10.9 AKT1 APC BRAF CTNNB1 EGFR ERBB2
14 thyroid cancer 10.8 AKT1 APC BRAF CTNNB1 EGFR GNAS
15 lung cancer 10.8 AKT1 BRAF EGFR ERBB2 HRAS KRAS
16 squamous cell carcinoma, head and neck 10.8 AKT1 BRAF CTNNB1 EGFR ERBB2 GNAS
17 pancreatic cancer 10.8 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
18 brain cancer 10.8 AKT1 BRAF CTNNB1 EGFR HRAS IDH1
19 glioblastoma 10.8 AKT1 BRAF EGFR ERBB2 HRAS IDH1
20 prostate cancer 10.8 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
21 bladder urothelial carcinoma 10.8 AKT1 BRAF CTNNB1 ERBB2 HRAS IDH1
22 endometrial cancer 10.8 AKT1 BRAF CTNNB1 EGFR ERBB2 HRAS
23 medulloblastoma 10.8 AKT1 APC CTNNB1 EGFR ERBB2 IDH1
24 squamous cell carcinoma 10.7 AKT1 BRAF CTNNB1 EGFR ERBB2 HRAS
25 pancreas adenocarcinoma 10.7 AKT1 CTNNB1 EGFR ERBB2 GNAS HRAS
26 endocrine gland cancer 10.7 AKT1 CTNNB1 EGFR ERBB2 GNAS HRAS
27 cervical cancer 10.7 AKT1 CTNNB1 ERBB2 GNAS HRAS MTOR
28 esophageal cancer 10.7 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
29 respiratory system cancer 10.7 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
30 gastrointestinal system cancer 10.7 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
31 suppression of tumorigenicity 12 10.7 AKT1 BRAF CTNNB1 HRAS IDH1 PIK3CA
32 adenoid cystic carcinoma 10.7 AKT1 CTNNB1 ERBB2 HRAS IDH1 KRAS
33 adamantinoma of long bones 10.7 APC BRAF CTNNB1 EGFR ERBB2 KRAS
34 lung squamous cell carcinoma 10.7 AKT1 BRAF EGFR HRAS KRAS PIK3CA
35 myeloma, multiple 10.7 AKT1 BRAF HRAS IDH1 IDH2 KRAS
36 leukemia, acute myeloid 10.7 AKT1 HRAS IDH1 IDH2 KRAS MTOR
37 ovarian cancer 10.7 AKT1 BRAF CTNNB1 EGFR ERBB2 KRAS
38 renal cell carcinoma, papillary, 1 10.7 BRAF ERBB2 HRAS MTOR NRAS PIK3CA
39 sarcoma 10.7 BRAF CTNNB1 HRAS KRAS MTOR PIK3CA
40 breast adenocarcinoma 10.7 AKT1 EGFR ERBB2 KRAS PIK3CA PTEN
41 melanoma, cutaneous malignant 1 10.7 BRAF CTNNB1 HRAS MAP2K1 NRAS PIK3CA
42 glioblastoma multiforme 10.7 AKT1 EGFR ERBB2 IDH1 MTOR PIK3CA
43 glioma 10.7 BRAF EGFR ERBB2 IDH1 IDH2 PIK3CA
44 carcinosarcoma 10.7 CTNNB1 ERBB2 HRAS KRAS PIK3CA PTEN
45 acneiform dermatitis 10.7 EGFR ERBB2 HRAS KRAS MAP2K1 NRAS
46 ovarian serous cystadenocarcinoma 10.7 AKT1 BRAF ERBB2 HRAS NRAS PIK3CA
47 endometrial adenocarcinoma 10.7 AKT1 CTNNB1 EGFR ERBB2 KRAS PTEN
48 uterine carcinosarcoma 10.7 CTNNB1 EGFR ERBB2 HRAS PIK3CA PTEN
49 gastrointestinal system disease 10.7 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
50 neuroblastoma 10.7 AKT1 CTNNB1 NRAS PIK3CA PTPN11 TP53

Graphical network of the top 20 diseases related to Large Intestine Cancer:



Diseases related to Large Intestine Cancer

Symptoms & Phenotypes for Large Intestine Cancer

GenomeRNAi Phenotypes related to Large Intestine Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 85)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.31 HRAS KRAS PIK3CA BRAF EGFR MTOR
2 Decreased viability GR00106-A-0 11.31 KRAS
3 Decreased viability GR00107-A-1 11.31 MAP2K1
4 Decreased viability GR00221-A-1 11.31 AKT1 HRAS KRAS PIK3CA RAF1 NRAS
5 Decreased viability GR00221-A-2 11.31 AKT1 HRAS KRAS PIK3CA RAF1
6 Decreased viability GR00221-A-3 11.31 AKT1 HRAS ERBB2 MAP2K1 NRAS
7 Decreased viability GR00221-A-4 11.31 AKT1 PIK3CA ERBB2 BRAF EGFR MTOR
8 Decreased viability GR00231-A 11.31 RAF1
9 Decreased viability GR00301-A 11.31 KRAS RAF1 BRAF
10 Decreased viability GR00342-S-1 11.31 MAP2K1 MTOR
11 Decreased viability GR00342-S-2 11.31 MAP2K1 MTOR
12 Decreased viability GR00342-S-3 11.31 MAP2K1
13 Decreased viability GR00381-A-1 11.31 KRAS BRAF
14 Decreased viability GR00402-S-2 11.31 AKT1 HRAS KRAS PIK3CA RAF1 ERBB2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-105 11.1 MTOR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-107 11.1 SMAD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-11 11.1 CTNNB1 MTOR SMAD4 KRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-110 11.1 BRAF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-113 11.1 CTNNB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-118 11.1 PTPN11
21 Increased shRNA abundance (Z-score > 2) GR00366-A-120 11.1 KRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-121 11.1 PTPN11
23 Increased shRNA abundance (Z-score > 2) GR00366-A-127 11.1 IDH1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-133 11.1 APC
25 Increased shRNA abundance (Z-score > 2) GR00366-A-136 11.1 IDH1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-138 11.1 IDH1 PTPN11
27 Increased shRNA abundance (Z-score > 2) GR00366-A-147 11.1 IDH1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-149 11.1 BRAF PTPN11
29 Increased shRNA abundance (Z-score > 2) GR00366-A-151 11.1 PTEN
30 Increased shRNA abundance (Z-score > 2) GR00366-A-152 11.1 PTEN
31 Increased shRNA abundance (Z-score > 2) GR00366-A-157 11.1 PIK3CA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-16 11.1 AKT1 IDH2 MTOR PIK3CA PTEN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-166 11.1 BRAF PIK3CA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-168 11.1 PTEN KRAS
35 Increased shRNA abundance (Z-score > 2) GR00366-A-172 11.1 IDH1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-176 11.1 IDH2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-177 11.1 BRAF CTNNB1 AKT1 IDH2 PIK3CA APC
38 Increased shRNA abundance (Z-score > 2) GR00366-A-178 11.1 PTPN11
39 Increased shRNA abundance (Z-score > 2) GR00366-A-190 11.1 PTPN11 PIK3CA
40 Increased shRNA abundance (Z-score > 2) GR00366-A-192 11.1 APC
41 Increased shRNA abundance (Z-score > 2) GR00366-A-194 11.1 BRAF
42 Increased shRNA abundance (Z-score > 2) GR00366-A-195 11.1 SMAD4
43 Increased shRNA abundance (Z-score > 2) GR00366-A-196 11.1 KRAS
44 Increased shRNA abundance (Z-score > 2) GR00366-A-197 11.1 CTNNB1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-199 11.1 IDH2
46 Increased shRNA abundance (Z-score > 2) GR00366-A-202 11.1 APC
47 Increased shRNA abundance (Z-score > 2) GR00366-A-21 11.1 SMAD4
48 Increased shRNA abundance (Z-score > 2) GR00366-A-214 11.1 PTEN
49 Increased shRNA abundance (Z-score > 2) GR00366-A-23 11.1 KRAS
50 Increased shRNA abundance (Z-score > 2) GR00366-A-25 11.1 SMAD4

MGI Mouse Phenotypes related to Large Intestine Cancer:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.61 AKT1 APC BRAF CTNNB1 EGFR ERBB2
2 growth/size/body region MP:0005378 10.57 AKT1 APC BRAF CTNNB1 EGFR ERBB2
3 cellular MP:0005384 10.55 AKT1 APC BRAF CTNNB1 EGFR ERBB2
4 endocrine/exocrine gland MP:0005379 10.55 AKT1 APC BRAF CTNNB1 EGFR ERBB2
5 behavior/neurological MP:0005386 10.54 AKT1 APC BRAF CTNNB1 ERBB2 GNAS
6 homeostasis/metabolism MP:0005376 10.54 AKT1 APC BRAF CTNNB1 EGFR ERBB2
7 embryo MP:0005380 10.51 AKT1 APC BRAF CTNNB1 EGFR ERBB2
8 mortality/aging MP:0010768 10.49 AKT1 APC BRAF CTNNB1 EGFR ERBB2
9 integument MP:0010771 10.48 AKT1 APC BRAF CTNNB1 EGFR ERBB2
10 craniofacial MP:0005382 10.46 APC BRAF CTNNB1 EGFR ERBB2 GNAS
11 immune system MP:0005387 10.46 AKT1 APC BRAF CTNNB1 EGFR GNAS
12 hematopoietic system MP:0005397 10.45 AKT1 APC BRAF CTNNB1 EGFR GNAS
13 neoplasm MP:0002006 10.43 AKT1 APC BRAF CTNNB1 EGFR ERBB2
14 digestive/alimentary MP:0005381 10.42 APC BRAF CTNNB1 EGFR ERBB2 HRAS
15 nervous system MP:0003631 10.39 AKT1 APC BRAF CTNNB1 EGFR ERBB2
16 muscle MP:0005369 10.37 AKT1 APC BRAF CTNNB1 EGFR ERBB2
17 adipose tissue MP:0005375 10.34 AKT1 APC BRAF EGFR GNAS MTOR
18 liver/biliary system MP:0005370 10.34 AKT1 APC BRAF CTNNB1 EGFR GNAS
19 normal MP:0002873 10.33 AKT1 APC BRAF CTNNB1 EGFR ERBB2
20 limbs/digits/tail MP:0005371 10.31 APC BRAF CTNNB1 EGFR ERBB2 GNAS
21 hearing/vestibular/ear MP:0005377 10.28 APC BRAF CTNNB1 EGFR GNAS KRAS
22 no phenotypic analysis MP:0003012 10.21 APC CTNNB1 EGFR GNAS HRAS KRAS
23 reproductive system MP:0005389 10.07 AKT1 APC BRAF CTNNB1 EGFR ERBB2
24 renal/urinary system MP:0005367 10.06 APC BRAF CTNNB1 EGFR GNAS HRAS
25 pigmentation MP:0001186 10.02 APC BRAF CTNNB1 EGFR KRAS NRAS
26 respiratory system MP:0005388 10 AKT1 BRAF CTNNB1 EGFR ERBB2 GNAS
27 skeleton MP:0005390 9.93 AKT1 APC BRAF CTNNB1 EGFR ERBB2
28 vision/eye MP:0005391 9.4 APC BRAF CTNNB1 EGFR KRAS MAP2K1

Drugs & Therapeutics for Large Intestine Cancer

Drugs for Large Intestine Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 898)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tegafur Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 17902-23-7 5386
2
Fluorouracil Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 51-21-8 3385
3
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
4
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
5
Ethiodized oil Approved, Investigational Phase 4,Phase 2 8008-53-5
6
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112887-68-0 104758
7
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
8
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
9
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 205923-56-4 56842117 2333
10
Phytonadione Approved, Investigational Phase 4,Phase 2,Phase 1 84-80-0 4812 5284607
11
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
12
Iodine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7553-56-2 807
13
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
14
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
15
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
16
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
17
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 114-07-8 12560
18
Bisacodyl Approved Phase 4,Phase 3,Not Applicable 603-50-9
19
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
20 tannic acid Approved Phase 4,Phase 2,Phase 1,Not Applicable
21
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
22
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 169590-42-5 2662
23
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
24
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 437-38-7 3345
26
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
27
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable,Early Phase 1 2078-54-8 4943
28
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
29
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
30
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
31
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
32
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 175805 71273
33
Ketorolac Approved Phase 4,Phase 2,Not Applicable 66635-83-4, 74103-06-3 3826
34
Hydromorphone Approved, Illicit Phase 4,Phase 2 466-99-9 5284570
35
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
36
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
37
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
38
Zinc Approved, Investigational Phase 4,Phase 3,Not Applicable 7440-66-6
39
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
40
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
41
Indomethacin Approved, Investigational Phase 4,Phase 1,Phase 2 53-86-1 3715
42
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
43
Magnesium citrate Approved Phase 4,Phase 3,Not Applicable 3344-18-1
44
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
45
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
46
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 51-43-4 5816
47
Racepinephrine Approved Phase 4,Phase 2,Phase 1,Not Applicable 329-65-7 838
48
Ranibizumab Approved Phase 4 347396-82-1 459903
49 Apricot Approved Phase 4
50
Sodium sulfate Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 7757-82-6

Interventional clinical trials:

(show top 50) (show all 4679)
# Name Status NCT ID Phase Drugs
1 Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
2 A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer Unknown status NCT02887365 Phase 4 tegafur-uracil
3 Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
4 Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
5 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
6 New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
7 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
8 Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Unknown status NCT00868569 Phase 4
9 Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
10 Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Unknown status NCT02575378 Phase 4 Metronimic chemotherapy plus Chinese Traditional Medicine;Metronimic chemotherapy
11 Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01972490 Phase 4 avastin+chemotherapy of mFOLFOX6 or FOLFIRI;chemotherapy of mFOLFOX6 or FOLFIRI
12 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
13 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
14 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
15 Preoperative Assessment of Colon Tumor Unknown status NCT00114829 Phase 4
16 Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4 comparing 2 drugs on their effect on the bowel preparation for colonoscopy
17 Intravenous Iron for Correction of Anaemia After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
18 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
19 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
20 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
21 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
22 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
23 Dissemination of Colorectal Cancer Screening to Primary Care Physicians Completed NCT00441311 Phase 4
24 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
25 Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population Completed NCT01557101 Phase 4
26 Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles Completed NCT00868816 Phase 4 12 cycles of oxaliplatine based adjuvant chemotherapy;8 cycles of oxaliplatine based adjuvant chemotherapy
27 Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer Completed NCT00928928 Phase 4
28 Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Completed NCT00559676 Phase 4 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
29 A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer Completed NCT02567331 Phase 4 Capecitabine
30 Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients Completed NCT00473980 Phase 4 Indomethacin, celecoxib, esomeprazole
31 A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer Completed NCT01695772 Phase 4 5-FU based doublet chemotherapy;bevacizumab
32 A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer. Completed NCT00502671 Phase 4 capecitabine [Xeloda]
33 Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer Completed NCT00869271 Phase 4
34 Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer Completed NCT01493713 Phase 4
35 The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery Completed NCT00122720 Phase 4 Darbepoetin Alfa
36 Chemotherapy Combined With CIK Treating Colon Cancer Completed NCT03084809 Phase 4 Cytokine-induced killer cells+ FOLFOX4;FOLFOX4
37 Endo-Laparoscopic Approach Versus Conventional Open Surgery in Obstructing Left-sided Colon Cancer: RCT Completed NCT00654212 Phase 4
38 A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer Completed NCT02581423 Phase 4 Capecitabine
39 Inflammatory Response in Laparoscopic and Open Colectomy Completed NCT00942461 Phase 4
40 A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer Completed NCT01588990 Phase 4 Oxaliplatin;Capecitabine;Bevacizumab;Leucovorin;5-Fluouracil;Irinotecan
41 Nutrition for Colorectal Cancer Patients and Neutrophil Functions Completed NCT01831310 Phase 4
42 Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants Completed NCT00138060 Phase 4 irinotecan;5 fluorouracil
43 MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV Completed NCT00263055 Phase 4 oxaliplatin
44 Omega-3 Fatty Acids and Postoperative Complications After Colorectal Surgery Completed NCT00488904 Phase 4
45 CHOICE: Communicating Health Options Through Information and Cancer Education Completed NCT00134589 Phase 4
46 Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function Completed NCT02231203 Phase 4 Omegaven;Placebo
47 Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients Completed NCT01641458 Phase 4
48 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
49 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
50 I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal Cancer Completed NCT00677586 Phase 4

Search NIH Clinical Center for Large Intestine Cancer

Cochrane evidence based reviews: colorectal neoplasms

Genetic Tests for Large Intestine Cancer

Anatomical Context for Large Intestine Cancer

MalaCards organs/tissues related to Large Intestine Cancer:

41
Colon, Liver, Testes, Eye, Breast, Small Intestine, Lung

Publications for Large Intestine Cancer

Articles related to Large Intestine Cancer:

# Title Authors Year
1
Neoplastic sigmoid-uterine fistula. An exceptional complication of large intestine cancer. ( 28460202 )
2017
2
Surgery in 932 cases of large intestine cancer. ( 6414771 )
1983
3
The diagnostic pattern of DNA-content in the "borderline" neoplasm of the large intestine. ( 888945 )
1977
4
Symptoms of large-intestine cancer. ( 4176883 )
1968

Variations for Large Intestine Cancer

ClinVar genetic disease variations for Large Intestine Cancer:

6 (show top 50) (show all 843)
# Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.4012C> T (p.Gln1338Ter) single nucleotide variant Pathogenic rs121913327 GRCh37 Chromosome 5, 112175303: 112175303
2 APC NM_000038.5(APC): c.4012C> T (p.Gln1338Ter) single nucleotide variant Pathogenic rs121913327 GRCh38 Chromosome 5, 112839606: 112839606
3 PTEN NM_000314.6(PTEN): c.697C> T (p.Arg233Ter) single nucleotide variant Pathogenic rs121909219 GRCh37 Chromosome 10, 89717672: 89717672
4 PTEN NM_000314.6(PTEN): c.697C> T (p.Arg233Ter) single nucleotide variant Pathogenic rs121909219 GRCh38 Chromosome 10, 87957915: 87957915
5 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
6 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
7 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
8 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
9 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
10 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
11 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
12 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
13 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
14 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
15 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
16 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
17 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
18 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
19 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
20 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
21 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
22 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
23 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
24 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
25 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
26 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
27 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
28 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
29 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
30 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
31 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
32 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
33 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
34 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
35 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
36 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
37 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
38 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
39 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
40 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
41 KRAS NM_033360.3(KRAS): c.175G> A (p.Ala59Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121913528 GRCh37 Chromosome 12, 25380283: 25380283
42 KRAS NM_033360.3(KRAS): c.175G> A (p.Ala59Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121913528 GRCh38 Chromosome 12, 25227349: 25227349
43 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
44 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
45 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
46 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
47 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
48 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
49 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282
50 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh38 Chromosome 12, 25245348: 25245348

Expression for Large Intestine Cancer

Search GEO for disease gene expression data for Large Intestine Cancer.

Pathways for Large Intestine Cancer

Pathways related to Large Intestine Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 271)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.44 AKT1 APC BRAF CTNNB1 EGFR ERBB2
2
Show member pathways
14.31 AKT1 BRAF CTNNB1 EGFR ERBB2 HRAS
3
Show member pathways
14.14 AKT1 APC BRAF CTNNB1 EGFR ERBB2
4
Show member pathways
14.12 AKT1 BRAF EGFR ERBB2 GNAS HRAS
5
Show member pathways
14.01 AKT1 APC BRAF CTNNB1 EGFR ERBB2
6
Show member pathways
13.98 AKT1 BRAF EGFR ERBB2 GNAS HRAS
7
Show member pathways
13.97 AKT1 BRAF EGFR ERBB2 GNAS HRAS
8
Show member pathways
13.86 AKT1 BRAF CTNNB1 EGFR ERBB2 GNAS
9
Show member pathways
13.84 AKT1 BRAF EGFR ERBB2 GNAS HRAS
10
Show member pathways
13.81 AKT1 BRAF CTNNB1 EGFR ERBB2 HRAS
11
Show member pathways
13.76 AKT1 GNAS HRAS IDH2 KRAS MTOR
12
Show member pathways
13.76 AKT1 EGFR ERBB2 HRAS KRAS MTOR
13
Show member pathways
13.72 AKT1 BRAF CTNNB1 EGFR GNAS HRAS
14
Show member pathways
13.7 AKT1 EGFR ERBB2 GNAS HRAS KRAS
15
Show member pathways
13.68 AKT1 BRAF EGFR ERBB2 HRAS KRAS
16
Show member pathways
13.6 AKT1 EGFR ERBB2 GNAS HRAS KRAS
17
Show member pathways
13.6 AKT1 APC BRAF CTNNB1 EGFR ERBB2
18
Show member pathways
13.59 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
19
Show member pathways
13.57 AKT1 GNAS HRAS KRAS NRAS PIK3CA
20
Show member pathways
13.54 AKT1 BRAF EGFR ERBB2 GNAS HRAS
21
Show member pathways
13.4 AKT1 BRAF EGFR GNAS HRAS KRAS
22
Show member pathways
13.37 AKT1 EGFR ERBB2 MTOR PIK3CA PTEN
23
Show member pathways
13.37 AKT1 BRAF CTNNB1 EGFR GNAS HRAS
24
Show member pathways
13.37 AKT1 APC CTNNB1 EGFR ERBB2 GNAS
25
Show member pathways
13.37 AKT1